CSM Advisors LLC Cuts Gilead Sciences Stake by 73.8%

Institutional investor reduces holdings in biopharmaceutical company during Q3 2026

Mar. 17, 2026 at 8:19am

Got story updates? Submit your updates here. ›

CSM Advisors LLC, an investment management firm, reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 73.8% during the third quarter of 2026, according to a recent 13F filing with the Securities and Exchange Commission. The firm now owns 15,075 shares of the biopharmaceutical company's stock, down from 57,475 shares held previously.

Why it matters

Gilead Sciences is a major player in the biopharmaceutical industry, known for its antiviral therapies for HIV and viral hepatitis. Changes in institutional ownership of the company's stock can provide insights into market sentiment and potential shifts in the company's outlook.

The details

According to the 13F filing, CSM Advisors LLC sold 42,400 shares of Gilead Sciences during the third quarter, reducing its total holdings in the company by 73.8%. The firm's remaining stake in Gilead Sciences is valued at $1,674,000 as of the filing date.

  • CSM Advisors LLC filed the 13F report for the third quarter of 2026.

The players

CSM Advisors LLC

An investment management firm that previously held a significant stake in Gilead Sciences, Inc.

Gilead Sciences, Inc.

A biopharmaceutical company focused on the discovery, development, and commercialization of medicines in areas of high unmet medical need, particularly in antiviral therapies for HIV and viral hepatitis.

Got photos? Submit your photos here. ›

The takeaway

The reduction in CSM Advisors LLC's position in Gilead Sciences could signal a shift in market sentiment or a reallocation of the firm's investment portfolio. However, without additional context or commentary from the firm, it's difficult to draw definitive conclusions about the reasons behind the sale or the broader implications for Gilead Sciences.